{{cell.content}}
曲拉西利全国首方落地。
[1]Wilson BE,Jacob S,Yap ML et al.Estimates of global chemotherapy demands and corresponding physician workforce requirements for 2018 and 2040:a population-based study.Lancet Oncol 2019;20:769–780.
[2]中国临床肿瘤学会(CSCO)中西医结合专家委员会.抗肿瘤药物引起骨髓抑制中西医结合诊治专家共识.临床肿瘤学杂志2021:1020–1027.
[3]Epstein RS,Aapro MS,Basu Roy UK et al.Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression:Results from an Online Survey of Patients with Solid Tumors.Adv Ther 2020;37:3606–3618.
[4]Wang Y,Probin V,Zhou D.Cancer therapy-induced residual bone marrow injury-Mechanisms of induction and implication for therapy.Curr Cancer Ther Rev 2006;2:271–279.
[5]Ying Cheng,Lin Wu,DingZhi Huang.Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy(TRACES).2022 WCLC,Abstract EP08.02-078.
[6]中国临床肿瘤学会指南工作委员会.中国临床肿瘤学会(CSCO)小细胞肺癌诊疗指南2022.北京:人民卫生出版社,2022.
特别声明:本文为人民日报新媒体平台“人民号”作者上传并发布,仅代表作者观点。人民日报提供信息发布平台。
写下你的评论
{{cell.content}}
{{item.content}}
{{item.content}}